Pipeline
Our pipeline demonstrates the ability of our AI-driven drug discovery platform to create precision engineered, patient-centric therapeutic candidates.
Programme
Target
Late Discovery
IND-enabling
Phase 1/2
Phase 3 / Approved*
Exscientia Rights
* Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes.